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In order to develop evidence-based recommendations
for vaccination of pediatric patients with auto-immune and/
or auto-inflammatory diseases, a EULAR task force
performed a systematic literature review. Available evidence
was critically appraised using a customary scoring system
for the level of evidence. The strength of each recommen-
dation was determined.
The majority of papers considered influenza (44) or
pneumococcal (20) vaccination. Very few studies were
found for the live-attenuated vaccines. Considering com-
posite vaccines, it is recommended to adhere to national
guidelines for the meningococcal serogroup C conjugate,
Hib, pneumococcal, hepatitis A and B, DTaP, HPV,
Japanese encephalitis, tick-borne encephalitis, typhoid
fever, rabies and cholera vaccination (Grade C-D). Seaso-
nal influenza vaccination is recommended (Grade D).
Patients on anti-CD20 therapy must receive tetanus speci-
fic immunoglobulines when indicated, since rituximab
lowers responses to tetanus toxoid (Grade D).
Since the publication of these recommendations, we
concluded a randomised controlled trial for the effects
of booster MMR in 139 children (60 using MTX and 15
using a biological) with JIA in the age of 4 to 9 years.
Disease activity measured by the JADAS 27 did not differ
between the revaccinated and the non-vaccinated groups.
As expected seroprotection rates were higher in the
revaccinated group. Methotrexate and biologicals did not
affect humoral responses, but low numbers precluded
definite conclusions.
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